Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Breaking & Recent News Resverlogix Corp. T.RVX

Alternate Symbol(s):  RVXCF | T.RVX.W.A

Resverlogix Corp clinical-stage biotechnology company. The company is developing an advanced epigenetic drug called apabetalone for the treatment of patients with cardiovascular disease, diabetes mellitus, chronic kidney disease, peripheral artery disease, orphan diseases, and neurodegenerative diseases.


Recent & Breaking News (TSX:RVX)

Resverlogix Announces 3-Month Loan Extension

GlobeNewswire May 2, 2019

Resverlogix' BETonMACE Phase 3 Trial Successfully Reaches its Targeted 250 MACE Events

Thomson Reuters ONE April 18, 2019

Resverlogix' BETonMACE Phase 3 Trial Successfully Reaches its Targeted 250 MACE Events

GlobeNewswire April 18, 2019

Resverlogix Cognition Substudy of the BETonMACE Phase 3 Cardiovascular Trial Presented at the International Conference on Alzheimer’s & Parkinson’s Diseases

GlobeNewswire April 1, 2019

Resverlogix Announces $15.1 Million of Private Placements

GlobeNewswire April 1, 2019

Resverlogix Announces Ninth Positive Data Safety Monitoring Board Recommendation for Phase 3 Study of Apabetalone

GlobeNewswire March 27, 2019

Resverlogix Proudly Announces Funding for Phase 2 Trial Evaluating Apabetalone in Pulmonary Arterial Hypertension Led by Quebec Heart and Lung Institute – Laval University Researcher

GlobeNewswire March 18, 2019

Zenith Epigenetics Announces U.S. FDA Clearance of Investigational New Drug Application for ZEN-3694 in TNBC Program

GlobeNewswire March 18, 2019

Resverlogix Announces Participation at Prominent Industry and Investor Conferences

GlobeNewswire March 11, 2019

Resverlogix Closes $6.6 Million Private Placement with Shenzhen Hepalink

GlobeNewswire January 31, 2019

Resverlogix Announces Eighth Positive Data Safety Monitoring Board Recommendation For Phase 3 Study of Apabetalone

GlobeNewswire December 19, 2018

Resverlogix Announces Publication on Apabetalone in Atherosclerosis Journal

GlobeNewswire November 28, 2018

Resverlogix Closes $13.5 Million Private Placement

GlobeNewswire November 2, 2018

Resverlogix Announces Participation at Premier Kidney, Alzheimer’s Disease and Cardiovascular Conferences

GlobeNewswire October 22, 2018

Resverlogix Announces Voting Results from the 2018 Annual and Special Meeting of Shareholders

GlobeNewswire September 12, 2018

Resverlogix Presents at Clinical Trials in Alzheimer’s Disease (CTAD) Asia 2018

GlobeNewswire September 4, 2018

Resverlogix Announces $26 Million Private Placement

GlobeNewswire August 30, 2018

Resverlogix Supports Epigenetics Satellite Symposium and Provides Oral Presentation on Apabetalone at the European Society of Cardiology Congress 2018 in Munich

GlobeNewswire August 22, 2018

Resverlogix Announces Seventh Positive Recommendation From The Data Safety Monitoring Board For Phase 3 Study of Apabetalone

GlobeNewswire August 7, 2018

Resverlogix Intends to Pursue U.S. Listing

GlobeNewswire July 31, 2018